Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
Dietz J, Müllhaupt B, Buggisch P, Graf C, Peiffer KH, Matschenz K, Schattenberg JM, Antoni C, Mauss S, Niederau C, Discher T, Trauth J, Dultz G, Schulze Zur Wiesch J, Piecha F, Klinker H, Müller T, Berg T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C; German HCV Resistance Study Group; University Hospitals; Academic Hospitals; Local study sites (private practices), Germany. Dietz J, et al. Among authors: klinker h. J Hepatol. 2023 Jan;78(1):57-66. doi: 10.1016/j.jhep.2022.08.016. Epub 2022 Aug 27. J Hepatol. 2023. PMID: 36031158
Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry.
Tacke F, Klinker H, Boeker KHW, Merle U, Link R, Buggisch P, Hüppe D, Cornberg M, Sarrazin C, Wedemeyer H, Berg T, Mauss S; DHC-R. Tacke F, et al. Among authors: klinker h. Hepatol Commun. 2022 Sep;6(9):2488-2495. doi: 10.1002/hep4.2015. Epub 2022 Jun 5. Hepatol Commun. 2022. PMID: 35666055 Free PMC article.
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
Wiegand J, Buggisch P, Mauss S, Boeker KHW, Klinker H, Müller T, Günther R, Serfert Y, Manns MP, Zeuzem S, Berg T, Hinrichsen H, C-Registry GH. Wiegand J, et al. Among authors: klinker h. Eur J Gastroenterol Hepatol. 2019 Nov;31(11):1424-1431. doi: 10.1097/MEG.0000000000001426. Eur J Gastroenterol Hepatol. 2019. PMID: 31589184
Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry.
Hinrichsen H, Stoehr A, Cornberg M, Klinker H, Heyne R, John C, Simon KG, Guenther V, Martin K, Witte V, Zeuzem S. Hinrichsen H, et al. Among authors: klinker h. Eur J Gastroenterol Hepatol. 2021 Mar 1;33(3):415-423. doi: 10.1097/MEG.0000000000001759. Eur J Gastroenterol Hepatol. 2021. PMID: 32345848 Free PMC article.
Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions.
Dietz J, Vermehren J, Matschenz K, Buggisch P, Klinker H, Schulze Zur Wiesch J, Hinrichsen H, Peiffer KH, Graf C, Discher T, Trauth J, Schattenberg JM, Piecha F, Mauss S, Niederau C, Müller T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Dietz J, et al. Among authors: klinker h. Liver Int. 2020 Jul 8. doi: 10.1111/liv.14591. Online ahead of print. Liver Int. 2020. PMID: 32640072
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
Stein K, Stoehr A, Klinker H, Teuber G, Naumann U, John C, Heyne R, Serfert Y, Niederau C, Zeuzem S, Berg T, Wiegand J; German Hepatitis C-Registry. Stein K, et al. Among authors: klinker h. Eur J Gastroenterol Hepatol. 2022 Jan 1;34(1):76-83. doi: 10.1097/MEG.0000000000001923. Eur J Gastroenterol Hepatol. 2022. PMID: 32956186
220 results